Page 60 - EF600

Te interesa publirreportaje Nova Biomedical: líder mundial en pruebas diagnósticas de sangre total para el punto de atención (point-of-care \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\[POC\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\]) Nova Biomedical es una empresa americana privada de diagnóstico in vitro (IVD) que fue fundada en 1976 y que actualmente es líder mundial en el desarrollo de biosensores de un solo uso para sangre total, gracias a su compromiso con la investigación y a la mejora constante de sus productos. «La avanzada tecnología desarrollada por Nova está guiada por la participación con las comunidades clínicas y médicas» Joan Marsal, General Manager de Nova Biomedical Iberia, explica que «en la úl- tima década, la tasa de crecimiento de nuestra compañía ha sido el triple que el crecimiento del mercado IVD. Por otro lado, Nova Biomedical es la empresa privada fabricante del sector IVD más grande de los Estados Unidos y la terce- ra a nivel mundial». Una empresa con presencia global Nova está presente en más de 100 países a través de filiales propias o dis- tribuidores, que se aseguran de proporcionar información sobre sus pro- ductos, realizar demostraciones y brindar un soporte técnico completo. «El rápido crecimiento de Nova —puntualiza Joan— se debe al compromiso cor- porativo de brindar a nuestr@s client@s algunas de las tecnologías más avan- 58 junio 2021 – el farmacéutico n.o 600 ©2021 Ediciones Mayo, S.A. Todos los derechos reservados